Quantamental Technologies LLC Purchases New Shares in Clovis Oncology (NASDAQ:CLVS)

Quantamental Technologies LLC purchased a new stake in Clovis Oncology (NASDAQ:CLVS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,546 shares of the biopharmaceutical company’s stock, valued at approximately $53,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. raised its holdings in shares of Clovis Oncology by 6.3% in the second quarter. Oppenheimer & Co. Inc. now owns 29,955 shares of the biopharmaceutical company’s stock valued at $445,000 after buying an additional 1,782 shares during the last quarter. Ropes Wealth Advisors LLC bought a new stake in Clovis Oncology during the 2nd quarter worth about $27,000. Aperio Group LLC bought a new stake in Clovis Oncology during the 2nd quarter worth about $48,000. Bank of Montreal Can raised its holdings in Clovis Oncology by 55.8% during the 2nd quarter. Bank of Montreal Can now owns 9,652 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 3,457 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its holdings in Clovis Oncology by 17.9% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 24,333 shares of the biopharmaceutical company’s stock worth $871,000 after purchasing an additional 3,700 shares during the last quarter. 91.69% of the stock is owned by institutional investors and hedge funds.

Shares of Clovis Oncology stock traded up $0.07 during trading on Friday, hitting $5.78. 58,009 shares of the company were exchanged, compared to its average volume of 3,114,332. The firm has a market capitalization of $315.39 million, a P/E ratio of -0.80 and a beta of 1.91. Clovis Oncology has a 1-year low of $4.98 and a 1-year high of $34.63. The firm’s fifty day moving average price is $6.97 and its 200 day moving average price is $16.33. The company has a debt-to-equity ratio of 8.04, a current ratio of 3.57 and a quick ratio of 3.32.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.57). The company had revenue of $32.98 million for the quarter, compared to analyst estimates of $34.92 million. Clovis Oncology had a negative return on equity of 372.68% and a negative net margin of 332.18%. Clovis Oncology’s quarterly revenue was up 38.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.94) earnings per share. As a group, equities research analysts anticipate that Clovis Oncology will post -7.51 earnings per share for the current year.

In other news, insider Lindsey Rolfe sold 1,728 shares of the business’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $14.70, for a total transaction of $25,401.60. Following the completion of the transaction, the insider now directly owns 23,319 shares in the company, valued at approximately $342,789.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James C. Blair bought 40,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were bought at an average price of $5.84 per share, with a total value of $233,600.00. Following the completion of the transaction, the director now directly owns 33,439 shares in the company, valued at approximately $195,283.76. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 107,800 shares of company stock valued at $612,094 and have sold 2,597 shares valued at $30,139. 8.30% of the stock is currently owned by insiders.

CLVS has been the subject of several recent research reports. ValuEngine raised Clovis Oncology from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Bank of America cut Clovis Oncology from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $13.00 to $7.00 in a report on Tuesday, August 13th. BidaskClub cut Clovis Oncology from a “sell” rating to a “strong sell” rating in a report on Saturday, July 27th. G.Research reissued a “buy” rating on shares of Clovis Oncology in a report on Friday, August 2nd. Finally, Piper Jaffray Companies reissued a “neutral” rating on shares of Clovis Oncology in a report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. Clovis Oncology currently has an average rating of “Hold” and an average price target of $25.09.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Further Reading: Mutual Funds

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.